PTC Therapeutics Provides Corporate Update and Reports Second Quarter 2025 Financial Results

– European and FDA approval of Sephience™ (sepiapterin) with broad labeling for PKU –

– Global launch underway in Europe and U.S. –

– Total Q2 Revenue of $179M –

Read more at prnewswire.com